Galectin‐3, Metabolic Risk, and Incident Heart Failure: The ARIC Study
Authors:
- Justin B. Echouffo‐TcheuguiJEJustin B. Echouffo‐Tcheugui
- Sui ZhangSZSui Zhang
- Roberta FloridoRFRoberta Florido
- James S. PankowJPJames S. Pankow
- Erin D. MichosEMErin D. Michos
- Vijay NambiVNVijay Nambi
- Gary GerstenblithGGGary Gerstenblith
- Wendy S. PostWPWendy S. Post
- Roger S. BlumenthalRBRoger S. Blumenthal
- Christie M. BallantyneCBChristie M. Ballantyne
- Josef CoreshJCJosef Coresh
Open Access
- 19 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (6) , e031607
Abstract
Background: It is unclear how metabolic syndrome (MetS) and diabetes affect Gal‐3 (galectin 3) levels and the resulting implications for heart failure (HF) risk. We assessed relationships of MetS and diabetes with Gal‐3, and their joint associations with incident HF. Methods and Results: We included 8445 participants without HF (mean age, 63 years; 59% men; 16% Black race) at ARIC (Atherosclerosis Risk in Communities) study visit 4 (1996–1999). We categorized participants as having MetS only, MetS with diabetes, or neither, and by quartiles of MetS severity Z score. We assessed cross‐sectional associations of metabolic risk categories with high Gal‐3 level (≥75th percentile) using logistic regression. We used Cox regression to evaluate combined associations of metabolic risk categories and Gal‐3 quartiles with HF. In cross‐sectional analyses, compared with no MetS and no diabetes, MetS only (odds ratio [OR], 1.24 [95% CI, 1.10–1.41]) and MetS with diabetes (OR, 1.59 [95% CI, 1.32–1.92]) were associated with elevated Gal‐3. Over a median follow‐up of 20.5 years, there were 1749 HF events. Compared with individuals with neither diabetes nor MetS and with Gal‐3 in the lowest quartile, the combination of MetS with diabetes and Gal‐3 ≥75th percentile was associated with a 4‐fold higher HF risk (hazard ratio, 4.35 [95% CI, 3.30–5.73]). Gal‐3 provided HF prognostic information above and beyond MetS, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity cardiac troponin T, and CRP (C‐reactive protein) (ΔC statistic for models with versus without Gal‐3: 0.003; P =0.004). Conclusions: MetS and diabetes are associated with elevated Gal‐3. The HF risk significantly increased with the combination of greater metabolic risk and higher Gal‐3.Keywords
This publication has 46 references indexed in Scilit:
- Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individualsDiabetologia, 2019
- Galectin‐3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) StudyResearch and Practice in Thrombosis and Haemostasis, 2017
- Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk In Communities Study and Jackson Heart StudyDiabetologia, 2017
- Relationship of galectin-3 with obesity, IL-6, and CRP in womenJournal of Endocrinological Investigation, 2016
- Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor?Journal of Endocrinological Investigation, 2014
- Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese miceCytokine, 2014
- Plasma Galectin 3 and Heart Failure Risk in the Physicians' Health StudyEuropean Journal of Heart Failure, 2013
- The Population Burden of Heart Failure Attributable to Modifiable Risk FactorsJACC, 2012
- Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the CommunityJACC, 2012
- MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORSStatistics in Medicine, 1996